. Author manuscript; available in PMC: 2014 Aug 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2013 May 6;19(8):1159–1166. doi: 10.1016/j.bbmt.2013.04.026

Table 4.

Effect of increasing mean total MPA Css as fixed covariate on clinical outcomes occurring after day 25^a

	Donor Type
	Related (N=132)		Unrelated (N=176)
	OR/HR (95% CI)	P-value	OR/HR (95% CI)	P-value
Day 28 T cell chimerism < 50%	0.83 (0.38–1.82)	0.63	1.39 (0.82–2.37)	0.23
Acute GVHD 2–4	0.86 (0.56–1.32)	0.48	0.79 (0.59–1.07)	0.13
Acute GVHD 3–4	1.50 (0.62–3.65)	0.37	0.54 (0.29–1.01)	0.05
Chronic GVHD	0.68 (0.47–0.99)	0.04	0.97 (0.75–1.27)	0.84
Relapse	1.07 (0.74–1.55)	0.73	1.06 (0.76–1.47)	0.75
Neutrophil nadir	1.53 (0.90–2.61)	0.12	0.87 (0.62–1.24)	0.45
CMV reactivation	1.00 (0.63–1.59)	0.99	0.88 (0.64–1.19)	0.40
Non-relapse mortality	0.68 (0.35–1.34)	0.27	0.58 (0.39–0.86)	0.007
Overall mortality	1.01 (0.72–1.43)	0.96	0.78 (0.61–1.01)	0.06

MPA Css fit as continuous variable (truncated at 97.5^th percentile to avoid outliers); HR per unit of MPA Css (μg/mL), adjusted for Kahl disease risk, antigen/2-allele mismatch, mean CNI concentration during week 2, year of transplant, female donor to male patient, tacrolimus prophylaxis, and fludarbine in conditioning (related donors only). Mean CNI week 2 fit as continuous variable, rescaled as standard deviation units to account for difference between cyclosporine and tacrolimus concentrations.